New data from the NATALEE trial reinforce the efficacy of ribociclib in combination with endocrine therapy for HR-positive, HER2-negative early breast cancer. With a median follow-up of 33.3 months, the final preplanned analysis confirms a significant improvement in invasive disease-free survival (iDFS) compared to endocrine therapy alone.
Key Findings:
✅ 25% reduction in risk of invasive disease recurrence or death (HR: 0.749, P = 0.0012).
✅ 3-year iDFS rates: 90.7% with ribociclib vs. 87.6% with endocrine therapy alone.
✅ Benefit observed across all key subgroups, including disease stage and nodal status.
✅ Distant DFS and recurrence-free survival (RFS) favored ribociclib.
✅ No new safety signals with long-term follow-up.
These findings continue to support ribociclib as an important adjuvant treatment option in early-stage breast cancer, offering a potentially practice-changing approach for improving patient outcomes.
Thanks to the dedicated research teams and investigators for advancing treatment strategies in breast cancer care. Their work paves the way for more effective and personalized treatment approaches.
For more information: https://lnkd.in/ew9YymrC
